Ebola vaccination in DRC.
Photo: ©UN Photo/Martine Perret


<< First < Previous Page 1 Page 2 Next > Last >>
Due to the urgent public health need for a prequalified Ebola vaccine, WHO has accelerated prequalification for the Ebola vaccine Ervebo by reviewing safety and efficacy data.

For the first time, an Ebola vaccine has been prequalified by the World Health Organization (WHO) in November 2019. This is a critical step that will help speed up its licensing, access and roll-out in countries most at risk of Ebola outbreaks. It is the fastest vaccine prequalification process ever conducted by WHO.

“Prequalification” means that the vaccine meets WHO standards for quality, safety and efficacy. United Nations agencies and Gavi, the Vaccine Alliance, can procure the vaccine for at-risk countries based on this WHO recommendation.

Two days earlier, the European Commission decided to grant a conditional marketing authorisation for the vaccine, following the recommendation from the European Medicines Agency (EMA). Representatives from the prequalification team participated in the EMA evaluation process to address programmatic suitability for at-risk countries in Africa.

The injectable Ebola vaccine, Ervebo, is manufactured by Merck (known as MSD outside the US and Canada).

<< First < Previous Page 1 Page 2 Next > Last >>